Evaluating financial challenges and quality of life in patients with neuroendocrine tumors
Financial Toxicity and Patient-Reported Outcomes in Italian Patients Affected by Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN)
This study looks at how the costs of treatment and travel affect the quality of life for patients in Italy with gastroenteropancreatic neuroendocrine tumors during their first year of care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS San Raffaele Academic / other |
| Drugs / interventions | sunitinib, chemotherapy |
| Locations | 1 site (Milan) |
| Trial ID | NCT05334290 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the financial toxicity experienced by Italian patients diagnosed with gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) during their first year of treatment. It will explore the correlation between financial burdens, patient-reported outcomes, and overall quality of life. The study recognizes the unique challenges faced by GEP-NEN patients, including the costs associated with long-distance travel to specialized treatment centers and the emotional impact of their diagnosis. By gathering data on these factors, the study seeks to provide insights into the financial and psychological aspects of living with GEP-NEN.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have recently been diagnosed with GEP-NEN and are eligible for treatment.
Not a fit: Patients under 18 years old or those whose treatment involves only surveillance or best supportive care may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify financial burdens that impact the quality of life for patients, leading to improved support and resources.
How similar studies have performed: While financial toxicity in cancer care is a recognized issue, this specific focus on GEP-NEN is relatively novel and has not been extensively studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥18 years of age * New diagnosis of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) * Patients who are candidates for surgical and/or medical treatment \[including somatostatin analogues (SAA), peptide recector radionuclide therapy (PRRT), target therapies (everolimus or sunitinib) and chemotherapy\]; * Signed informed consent Exclusion Criteria: * Age \< 18 years * Patients diagnosed with GEP-NEN who are candidates for a surveillance management. * Patients diagnosed with GEP-NEN who are candidates for best supportive care and/or have a life expectancy \< 6 months.
Where this trial is running
Milan
- IRCCS Ospedale San Raffaele — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Stefano Partelli, Professor — San Raffaele Hospital Milan
- Study coordinator: Stefano Partelli, Professor
- Email: partelli.stefano@hsr.it
- Phone: 0226437697
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.